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Abstract 
 
While the use of PROs in research is well established, many challenges lie ahead as their use 
is extended to other applications. There is consensus that health outcome evaluations that 
include PROs along with clinician reported outcomes and administrative data are necessary 
to inform clinical and policy decisions.  The initiatives presented in this paper underline 
evolving recognition that PROs play a unique role in adding the patient perspective along 
side clinical (e.g. blood pressure) and organisational (e.g. admission rates) indicators for 
evaluating the effects of new products, selecting treatments, evaluating quality of care and 
monitoring the health of the population. In this paper, we first explore the use of PRO 
measures to support drug approval and labeling claims. We critically evaluate the evidence 
and challenges associated with using PRO measures to improve health-care delivery at 
individual and population levels. We further discuss the challenges associated with selecting 
from the abundance of measures available, opportunities afforded by agreeing on common 
metrics for constructs of interest, and the importance of establishing an evidence base that 
supports integrating PRO measures across the healthcare system to improve outcomes.  We 
conclude that the integration of PROs as a key end point within individual patient care, 
healthcare organization and program performance evaluations, and population surveillance 
will be essential for evaluating whether increased healthcare expenditure is translating into 
better health outcomes.   
 
[224 words] 
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Key Messages 
 
 While the use of PROs in research is well established, many challenges lie 
ahead as their use is extended to a wide range of additional applications, such 
as the regulatory approval process of drugs and medical devices, the 
monitoring of the health of the populations and the quality of the health 
services, and supporting decision making in clinical settings.  
 A 3-step roadmap developed by the US FDA for PRO measurement in clinical 
trials demands: 1. understanding the disease or condition; 2. conceptualizing 
treatment benefits; and 3. adequate selection and development of PRO.  
 The England NHS Programme has provided evidence that the systematic 
collection of PRO is feasible at such a large scale, and that it provides relevant 
information about health services delivery. 
 Several general population studies in child and adolescent in Europe have 
informed the development and monitoring of policies and strategies at 
regional, national and international levels.  
 There is an increasing number of PROs and other health indicators assessing 
the same underlying construct but they are most frequently not scaled to the 
same metric. Interoperability of PROs is possible and necessary for 
comparability of results obtained in different settings, such as health surveys 
and medical records. 
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1. Introduction 
 
Patient Reported Outcomes (PROs) are measurements of health as reported by patients 
about themselves and include (but are not limited to) symptoms, functioning, health 
perceptions and health related quality of life [1]. Several thousand PRO measures are in 
existence and new ones are being developed every day [2]. PRO measures were originally 
developed, in part, to aid in evaluating and comparing the effectiveness of healthcare 
interventions. While the use of PROs in research is well established, many challenges lie 
ahead as their use is extended to other applications.  
 
Real time evaluation of patients’ preferences, health, well-being, and behaviour has the 
potential to inform clinical care and contribute to comparative effectiveness research 
embedded within real-world care delivery [3,4]. However, it remains unclear how to best 
aggregate and integrate patient-level PRO data to inform quality improvement and 
population health surveillance.  Standards of how PRO measures are selected, collected, 
interpreted, reported and merged with other clinical or administrative datasets are needed 
to ensure that results are valid and meaningful for clinical care and policy decision-making.    
 
Global organizations are addressing these challenges and translating the wealth of expertise 
in PROs into areas as different as quality improvement, clinical care, and population health 
surveillance. Initiatives such as the PROMs programme in the England [5], the integration of 
Patient Reported Outcomes Measurement Information System (NIH-PROMIS) measures in 
electronic clinical records [6], the routine use of PRO measures in geriatric and mental 
health settings [7,8], and the inclusion of generic measures in national health surveys are 
testimony of the vital role of PROs in assessing health outcomes.  
 
In this paper, we first explore the use of PRO measures to support drug approval and 
labeling claims. We critically evaluate the evidence and challenges associated with using 
PRO measures to improve health-care delivery at individual and population levels. We 
conclude with reflections on the challenges associated with selecting from the abundance of 
measures available, opportunities afforded by agreeing on common metrics for constructs 
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of interest, and the importance of establishing an evidence base that supports integrating 
PRO measures across the healthcare system to improve outcomes.   
 
Use of PRO Measures to Support the Approval of Drugs, Labels and 
Promotional Claims (Laurie Burke) 
 
PRO measures play a vital role in the evaluation of medical intervention benefit and risk.  In 
the US, for instance, any medical product claim of improvements in symptoms or daily 
functioning must be based on patient-reported assessments that are well-defined and 
reliable, and are used to define study endpoints in adequate and well-controlled studies.  
Even when survival is the primary objective of a study, PRO assessments are necessary to 
characterize symptoms and daily functioning in those whose life may be extended by 
treatment.  From a regulatory perspective, the only situations in which PROs are not 
relevant are when patients cannot respond for themselves (e.g., in young children) or when 
biomarkers or clinical assessment are the only outcomes of disease activity (e.g., early after 
diagnosis for some hematologic disorders).    
 
Clinical trial measurement science continues to evolve since the entry of the efficacy 
requirement for medical product marketing in the US in 1962 [9]. PRO measure validation is 
a continuous process with evidence continuing to be compiled throughout the instrument’s 
lifespan.  Planning PRO measurement, well in advance of when it is needed (i.e., with the 
phase 3 study protocol) can help mitigate a number of challenges as described below. 
 
First, a certain minimum set of information needs to be available before the phase 3 
protocol. This includes evidence of content validity (i.e., that the score represents the 
outcome/concept of interest in the context of use), test-retest reliability in stable patients 
similar to those who will be enrolled in the clinical trial at baseline, and basic cross-sectional 
construct validity that demonstrates the relationship of the score to other trial endpoints.  
Longitudinal measurement properties are also important but, if necessary, can be explored 
using blinded clinical trial data, with some risk to the trial outcome (e.g., if ability to detect 
change is inadequate).  The interpretation of trial findings is dependent on establishing 
ISOQOL 2014, Berlin. Plenary Session: “PROs: contributing to better services and better societies” 
 
6 
 
thresholds for meaningful change (i.e., defining responders).  Decision-makers must 
interpret study results to determine the importance of the treatment effect in the context 
of their patient situations or population characteristics and the value of the treatment in 
comparison to other treatments.   
 
To facilitate this process, the US Food and Drug Administration (FDA) has published a three-
step “roadmap” to evaluate and develop PRO measures to support medical product 
labelling and advertising  [10] (Table 1). The first step, “Understanding the Disease or 
Condition”, often overlooked in its entirety, represents the process of gathering relevant 
information that determines the clinical trial context of use.  Most importantly for PRO 
measures, it includes the process of gathering a full understanding of the patient/caregiver 
perspectives on the definition of treatment benefit, benefit-risk trade-offs, and the impact 
of the disease on daily life and function.  The second step, “Conceptualizing Treatment 
Benefit”, consolidates the relevant background information from the previous step to 
determine the specific population to be studied and the appropriate study design. This step 
includes identification of the full set of outcomes, PRO and other, to define study endpoints 
(primary and secondary) that need to be tested in that population to fully understand 
treatment benefit in light of the possible risks that will be discovered in the clinical trial.  
Each outcome needs to be identified in terms of the concept represented and its context of 
use including relative order among all study endpoints included in the statistical analysis. 
<Table 1> 
 
With the context of use and the concept of interest fully identified, the third step, 
“Selecting/Developing Outcome Measures,” outlines the process of measure identification 
or development.  Measure qualification activities at European Medical Agency (EMA) and 
FDA, combined with advancements in measurement science, are improving the likelihood 
that an existing measure will be found.  If none exists, however, instrument modification or 
new measure development is required.  Because measures with content validity in the 
planned clinical trial context are needed before the onset of phase 3, early consideration of 
the roadmap is hoped to ensure the availability of adequate information for patients and 
other decision-makers about the impact of treatment on symptoms and functioning at the 
time of product availability.     
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Health Care Services: Improving Clinical Practice and Quality (Nick Black) 
 
The routine use of PROs linked to clinical practice has been driven by two principal motives: 
comparison of outcomes (usually hospitals) and improving the clinical management of 
individual patients. While the latter has been the main motivation in Sweden and the USA, 
use in England has centered around comparing the performance of providers [11]. The hope 
has been that PROs can increase productivity by avoiding unnecessary treatments and 
improving quality through service redesign and patient choice.  
 
Since 2009, use of PROs has been mandatory in the 250,000 patients undergoing one of four 
elective surgical operations funded by the English National Health Service (NHS) under the 
NHS PROMs programme. All patients are invited to complete a pre-operative questionnaire 
which queries socio-demographic characteristics, comorbidities, and includes a condition-
specific PRO and a generic PRO (the EQ-5D). Either three (hernia repair, varicose vein 
surgery) or six (hip and knee replacement) months after surgery patients are mailed another 
questionnaire that includes the two PROs plus questions on complications and single 
transitional items.  
 
Five years on, much has been learnt about the feasibility of the approach and about some 
methodological properties of PROs used in this way. First, although recruitment rates are 
modest (68% for hip and knee replacement; 45% for the minor procedures), this does not 
appear to bias the comparisons of hospitals’ outcome as these are adjusted for the factors 
associated with non-recruitment (over 75 years of age; deprived; non-white) [12]. Second, 
post-operative response is good (85% for hip and knee replacement; 65-75% for minor 
procedures) [13]. Third, despite some surgeons' concern that patients may confuse outcome 
(effectiveness) with their experience of the way care was delivered (humanity), there is only 
a weak association (r = 0.2) between PRO scores and patient reported experience measures 
(PREMs) [14]. In other words, PROs and PREMs measure different aspects and patients can 
and do distinguish these domains of quality. Fourth, the choice of metric derived from PROs 
makes a difference to the proportion of providers defined as ‘poor’. For example, for hip 
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replacement the mean risk-adjusted change in the disease-specific PRO classified 25% were 
more than 2 standard deviations (SD) from the overall mean. However, using the proportion 
of patients achieving a minimally important difference identified resulted in only 12% being 
classified as outliers [15]. If the goal is to avoid missing an outlier, then the former is best; if 
avoidance of mistakenly labelling a provider as an outlier is the priority, then the latter is the 
optimal approach. 
 
Experience with PROs has also shed light on aspects of health services delivery. First, 
although it was expected that increased surgical rates in an area would be associated with a 
decrease in the mean pre-operative severity of patients, no significant association was 
found (Figure 1) [16]. This suggests that the decision to operate is still largely determined by 
surgeons rather than reflecting patients’ self-reported need. Second, while the association 
between hospital volume and safety (such as operative mortality) is well-established, no 
such association has been found with effectiveness (i.e., risk-adjusted change in PROM 
scores) [17]. Third, little difference in outcomes has been observed between individual 
surgeons, though more outliers (i.e., > 3 SD from the expected) are detected than when 
post-operative mortality is used as the outcome [18]. And finally, despite widely held beliefs 
that competition results in better quality, no association has been seen between the 
amount of competition in a locality and mean risk-adjusted change in PRO scores [19]. 
<Figure 1> 
 
The NHS PROMs Programme, however, had no discernible impact on patient selection or 
outcomes over its first three years [20]. This may be for three reasons:  1) providers only 
started receiving feedback in the third year of the programme;  2) the quality of 
presentation of feedback was rather poor (indigestible spreadsheets); or 3) for these four 
procedures, there is little room for improvement – all hospitals and surgeons provide good 
quality care already. Greater differences with an associated greater scope for improvement 
are more likely with emergency surgical operations.  
 
One of the main research challenges ahead is a need to clarify expectations as to the routine 
use of PROs. A realist synthesis of the literature is underway [21] to help identify users’ aims 
and the theories underling their expectations. There are also methodological challenges to 
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address regarding the routine use of PROs in more taxing clinical areas such as long term 
conditions (with no before and after measurement feasible/appropriate), emergency 
conditions (with no before measurement possible) and dementia (where cognitive 
dysfunction limits the extent to which patients can contribute). 
 
Other challenges concerns policy and practice. There is a need to bring together the two 
principal reasons for using PROs – clinical management and provider performance 
assessment. Ensuring that future use combines both aims will enhance the quality of the 
data collected, patient and clinician engagement, and the potential benefits for policy-
makers [22]. These aims will be facilitated by the adoption of new data collection 
techniques that minimise data collection costs and offer timely feedback. Both clinical 
management and provider assessment would benefit from better presentation of output to 
result in actionable feedback.  
 
Well-being in Populations: The Case for Monitoring Child Mental Health (Ulrike Ravens-
Sieberer) 
 
Mental health constitutes “the foundation for well-being and effective functioning for an 
individual and for a community” [23]. A substantial proportion of mental health problems in 
adults originate early in life [24].  Although the health of children and adolescents has been 
continuously improving, children and adolescents today are more likely to experience social, 
emotional and behavioural difficulties resulting in range of disorders including depression,  
anxiety, disruptive disorders and eating disorders [25]. Monitoring children’s health and 
well-being is a promising strategy that can aid in early detection of hidden or manifest 
mental health problems [26,27]. Here, we make the case that PROs be used as an indicator 
of population health, albeit with acknowledgement that the use of positive mental health 
and well-being indicators has not deserved extensive attention [28]. 
 
Three European studies have developed and implemented a range of indicators to assess 
child and adolescent mental health and well-being. The Health Behaviour in School-aged 
Children (HBSC) Study, in collaboration with the WHO Regional Office for Europe, has been 
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collecting health information for 25 years in over 40 countries in Europe and North America 
[26,29,30]. The European KIDSCREEN project developed and implemented a standardized 
screening instrument for health-related quality of life (HRQL) in children and adolescents in 
13 European countries (Figure 2) [28]. The Flash Eurobarometer collected parent’s views on 
the mental health and well-being of their children in 27 EU member states in 2008 [31].  
<Figure 2> 
 
Such studies provide robust data on a wide range of child and adolescent health issues that 
can help inform the development of policies and strategies [32]. They also provide 
researchers, clinicians and policy makers with the knowledge necessary to evaluate and 
advance development of public health policy and practice at regional, national and 
international levels [33]. The WHO/HBSC Forum Series is a good example of how research 
data can be leveraged for policy making in WHO European member countries. In Forum 
meetings, HBSC data are used to promote discussion among international partners and 
facilitate the translation of research findings into effective policy-making and practice 
(www.hbsc.org). The products of these meetings are a synthesis report and policy 
statement, along with additional materials. Past reports have addressed healthy eating 
habits and physical activity (2006), social cohesion for mental well-being (2007), and socio-
environmentally determined health inequities (2009).  
 
Current research is illness-oriented and, as previously noted, the development of positive 
mental health indicators is largely still in its infancy. Too often, mental health is 
misconceptualized as the absence of mental disorders, as evidenced by the fact that existing 
measures used to assess population mental health are primarily “needs driven” and focus  
on “illness” and distress [34], such as delinquency, suicide, depression, rather than 
“wellness”. Lack of comparable measures, reporting methods, and cultural differences in  
perceptions (i.e., whether mental disorders are transient or not, and whether and how they 
require treatment in different countries and communities) also impede the reliable 
assessment of current trends.  
The RICHE Roadmap report on gaps and needs in child health research in Europe clearly 
identified several factors including: 1) the need for early detection (screening) and  
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monitoring; 2) the use of age- and culturally-appropriate instruments; and 3) the need to 
place a stronger focus on younger age groups. At present, measures are generally 
adolescent-focused and young children are generally underrepresented in international 
data sources. Monitoring of children’s mental health, along with screening tools to detect 
groups at higher risk for poor mental health is an important act of prevention and a 
promising strategy to detect negative developments [35].  
 
To date the effect of early childhood risk factors remains understudied, and research into 
factors associated with the development of mental disorders and the means by which they 
interact is necessary to develop effective primary prevention strategies and interventions. 
To obtain comprehensive and comparable information on the current health of children and 
adolescents today, a European health survey for children in all age groups (from infants to 
teenagers) needs to be established [35]. There is also a need for more European 
comparative longitudinal studies in specific health areas, to conduct meaningful cross-
cultural/cross country comparisons through the use of validated and routinely implemented 
indicators, and to further develop age-related indicators in specific areas [35].  
 
Monitoring the well-being of our youth is clearly important. Health indicators are a bridge 
between health policy and scientific information [36]. Effective mental health indicators can 
facilitate international comparisons and provide valuable information about the well-being 
of children, leading to better identification of vulnerable groups and areas needing support.  
Measuring well-being internationally can lead to greater acknowledgement of the 
importance of well-being in young people everywhere [35].  
 
Linking Population Health, Clinical Research, and Clinical Practice PROs 
Applications: The Call for a Common Metric (Chris Forrest) 
Several recent developments in the United States highlight the important role of PROs in 
population health, large-scale clinical research, and clinical practice. These include the 
nation’s health objectives (i.e., Healthy People 2020 [37]), the national clinical research 
network-of-networks,  funded by the Patient Centered Outcomes Research Institute (PCORI) 
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and called PCORnet [38], and an Institute of Medicine (IOM) report on the social and 
behavioral domains that should be included in all electronic health records [39] (IOM 2014). 
 
Healthy People is the U.S. government’s decennial national objectives for population health 
improvement and reduction of disparities [37]. Four domains provide the core set of 
measures for evaluating progress: 1) determinants of health; 2) general health status; 3) 
disparities; and 4) HRQL and well-being. Determinants of health subsume behavior, health 
services, social factors, and policy. General health status includes conventional indicators 
such as life expectancy, years of potential life lost, limitations of activity, and chronic disease 
prevalence. Disparities cover assessments of the health indicators by such factors as 
socioeconomic status, sex, sexual identity, race or ethnicity, age, disability, and geographic 
location. Lastly, for the first time, Healthy People added a focus on health-related quality of 
life. After reviewing measures of self-reported health, well-being, and participation, Healthy 
People 2020 selected the PROMIS® adult global health measure, which includes physical 
health scale and mental health scales [40], for monitoring objectives. The scales are turned 
into indicators by dichotomizing them at scores reflective of good or better self-reported 
physical or mental health. Healthy People 2020 has set targets for improving national adult 
self-reported health, is collecting data to enable monitoring of disparities in these indicators 
and is now considering extending these indicators to children and youth. 
 
In 2014, PCORI announced the launch of PCORnet, a national network of networks designed 
to conduct patient-centered outcomes research [38]. PCORnet includes 29 research 
networks that are harmonizing their data to a common data model. An example of one of 
the networks is PEDSnet, which includes 8 large pediatric health systems and 3 disease-
specific networks [41]. It is expected that PCORnet, when fully mature and conducting 
research, will include somewhere between 50-100 million Americans. The PCORnet 
common data model includes electronic health record data and PROs. It is envisioned that 
research networks will embed the collection of PROs into routine clinical care, and these 
measures will be used to describe study samples, to control for differences between groups, 
and to assess primary and secondary end-points in observational studies and clinical trials. 
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The IOM issued a report in November, 2014 proposing a concise set of self-reported social 
and behavioural determinants (SBD) of health that should be included in all patients’ 
electronic health records [39]. It is well recognized that social and behavioural factors are as 
important, and in some cases more important, than biomedical factors in determining 
health and health risk. Yet, they are not captured during medical encounters in any 
systematic way, which effectively precludes their use to improve patient care, leading to 
calls to create approaches for routinely characterizing patients’ psychosocial environment 
on a periodic basis [42]. Recognizing the opportunity to address this need, nine federal and 
foundation sponsors asked the IOM to assemble a committee of social science, clinical, and 
informatics experts to recommend a set of SBDs for inclusion in electronic health 
records. Placing priority on measures with the greatest clinical usefulness and feasibility for 
capture within the clinical workflow, the committee developed a parsimonious panel of 
complementary measures that when given in its entirety includes 24 questions, which 
would take about 5-10 minutes to complete before or during a medical encounter. The 
measures cover socio-demographic, psychological, behavioral, social relationship, and 
community factor dimensions, providing a comprehensive assessment of a patient’s 
psychosocial environment.  
 
As exciting as each of these new developments is, they all suffer from the challenge of 
measure selection. We lack a set of universally accepted measures for a comprehensive 
measurement of PROs, particularly addressing psychosocial constructs and quality of life. Some 
may argue that this is a strength of our field, as it reflects our ingenuity and creativity as 
scientists. However, imagine that the research networks in PCORnet choose to measure 
social isolation with measure A, while the clinical practices that adopt the IOM 
recommendations choose to measure the same concept with measure B. Although the two 
measures may assess the same underlying construct, they are not scaled to the same 
metric, rendering the data obtained in these two applications non-comparable. In 
informatics terms, the two measurement systems are not interoperable, which prevents 
facile integration of findings from research studies into clinical practice, meta-analyses using 
the two sources of data, and data sharing. 
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The proliferation of measures for the same construct creates a Tower of PRO-Babel that 
may be unnecessary. We argue that quality of life researchers should work together to 
agree on common metrics for constructs of interest. This is akin to saying that all 
temperature will be measured on the Kelvin scale, which allows devices to obtain 
assessments using Celsius or Fahrenheit scales assuming that they are then converted to the 
Kelvin scale (Table 2). In other words, use the measurement device of your choosing, but 
represent the data on the same scale. The PROMIS measurement system provides a set of 
common metrics to which PRO instruments that assess comparable constructs can be 
scaled. Each PROMIS measure undergoes item response theory calibration and national 
norming of the calibrated scale to a mean of 50 and standard deviation of 10. Any item or 
scale that measures the same domain as a given PROMIS measure can be transformed to 
the PROMIS T-score, allowing for users to collect data using the measure of their choice, but 
rendering it on a common metric. However, to date, this has been done for a minority of 
instruments [43].The convergence of electronic health record proliferation and integration 
of PROs into clinical practice, clinical research, and population health creates a new 
imperative for tearing down the Tower of PRO-Babel and erecting in its place a common 
language with common metrics. 
<Table 2> 
 
Discussion 
There is consensus that health outcome evaluations that include PROs along with clinician 
reported outcomes and administrative data are necessary to inform clinical and policy 
decisions.  The integration of PROs as a key end point within individual patient care, 
healthcare organization and program performance evaluations, and population surveillance 
will be essential for evaluating whether increased healthcare expenditure is translating into 
better health outcomes.   
The numerous PROs already developed offer an indication of the growth of the field, but in 
areas where there are multiple choices, this can lead to greater uncertainty and create 
additional barriers for to uptake.  We have identified gaps in PRO applications that can 
inform strategies to manage the selection, application, and interpretation of PROs.  
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Regardless of the setting or application, similar challenges exist in the widespread use and 
application of PROs. 
First, the use of particular measures to evaluate domains of interest, when measures are applied to 
new populations or contexts, should be supported by an evaluation of their metric properties in 
these new circumstances.  This resource-intensive activity is often overlooked when a 
measure is applied to a new patient population or context.  Second, guidance is needed for 
the selection of measures that are reliable, valid and responsive to change[44, 45].  
Standardisation of metrics is needed to facilitate comparisons. Finally, interpretation of 
scores is also critical as this will influence clinical and policy decisions, and in turn, the 
relevance of PROs for improving access and quality of care[19,45]. Identifying effective 
formats for the feedback of PRO data to stakeholders, and consensus on actions is a key 
intermediary step to achieving improvements in quality of care. 
These considerations underline several areas for future research and changes to healthcare 
policy. This includes facilitating the implementation of PROs with as regard to measure 
selection, ease of use, and feedback of recommendations that are actionable.  Further 
evaluation is also needed to determine how the choice of metrics influences the conclusions 
and changes in practice and to validate PRO data with comparisons to other sources of data.  
As the application of PROs in clinical care and health policy is relatively new, further 
research is needed to evaluate whether using them makes a difference. Studies addressing 
these issues are currently underway [21,47]. 
Finally, further mapping is needed to define governance and infrastructure to support 
collection and feedback of data so that PROs can inform a learning health care ecosystem 
[48]. Careful planning of how data from different sources will be merged and accessed, 
including consensus across electronic health records (HER) vendors and administrative 
databases, and a common coding system for PRO domains and items is also needed. The 
infrastructure and established processes also must ensure that the most vulnerable (e.g. 
elderly, those with learning difficulties or dementia) who are just as likely to benefit from 
healthcare improvements, are not excluded when PRO data are collected. Such an 
infrastructure will facilitate the application of PROs not only for clinical care and health 
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policy, but also to generate the evidence in support of the belief that incorporating the 
patient voice through PROs can help make things better. 
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Table 1. U.S. Food and Drug Administration (FDA) roadmap to Patient Focused Outcome 
Measurement in Clinical Trials. 
Understanding the disease 
or condition 
Conceptualizing treatment 
benefit 
Selecting/developing the 
outcome measure 
Natural history of the  
disease or condition 
• Onset, duration, resolution 
• Diagnosis 
• Pathophysiology 
• Range of manifestations 
Identify concept(s) of 
interest for meaningful 
treatment benefit, i.e., how 
a patient: 
• Survives 
• Feels (e.g., symptoms) 
• Functions 
Search for existing clinical 
outcome assessment 
measuring concept(s) of 
interest in context of use 
• Measure exists 
• Measure exists but needs to 
be modified 
• No measure exists 
• Measure under development 
Patient subpopulations  
• By severity 
• By onset 
• By comorbidities 
• By phenotype 
 
Define context of use for 
clinical trial 
• Disease/Condition entry 
criteria 
• Clinical trial design 
• Endpoint positioning 
Begin clinical outcome 
assessment development 
• Document content validity 
(qualitative or mixed methods 
research) 
• Evaluate cross-sectional 
measurement properties 
(reliability and construct 
validity) 
• Create user manual 
• Consider submitting to FDA 
for clinical outcome assessment 
qualification for use in 
exploratory studies 
Health care environment 
• Treatment alternatives 
• Clinical care standards 
• Health care system 
perspective 
Patient/caregiver 
perspectives 
• Definition of treatment 
benefit 
• Benefit-risk tradeoffs 
• Impact of disease 
Select clinical outcome 
assessment type 
• Patient-Reported Outcome 
(PRO) 
• Observer-Reported Outcome 
(ObsRO) 
• Clinician-Reported Outcome 
(ClinRO) 
• Performance Outcome 
(motor, sensory, cognition) 
Complete clinical outcome 
assessment development: 
• Document longitudinal 
measurement properties 
(construct validity, ability to 
detect change) 
• Document guidelines for 
interpretation of treatment 
benefit and relationship to 
claim 
• Update user manual 
• Submit to FDA for clinical 
outcome assessment 
qualification as effectiveness 
endpoint to support claims 
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Table 2.   Common metrics, and measurement tools for selected conceptual domains 
  
Conceptual Domain Common 
Metric 
Measurement Tools 
Length Meters  Metric ruler 
 Imperial unit ruler 
Blood Pressure Millimeters of 
mercury 
 Manual sphygmomanometers 
 Automated sphygmomanometers 
 Automated devices for self-
measurement at the wrist 
Physical Activity Metabolic 
Equivalent of 
Task (MET) 
minutes 
 Self-reported questionnaires 
 Actigraphs 
 Accelerometers 
Depressive Symptoms PROMIS T-Score  PROMIS Depression Short Form 
 Patient Health Question-9 (PHQ-9) 
 Beck Depression Inventory-II 
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Figure 1. Association between change between 2009/10 and 2011/12 in district utilisation 
rate and change in pre-operative severity (mean score in Patient Reported Outcome scores). 
 
OHS: Oxford Hip Score; OKS: Oxford Knee Score; AVVQ: Aberdeen Varicose Veins Questionnaire; EQ5D: EurQol 
5D. 
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Figure 2. Mental health problems and family affluence. 
 
FAS: Family Affluence Scale; SDQ: Strengths and Difficulties Questionnaire. Reproduced with permission from 
Ravens-Sieberer et al. 2008, p.37 
 
 
 
